Asthma

Two consecutive CHEST studies showed combination therapy's expanding portfolio.

Regeneron and Sanofi released more positive phase 3 trial results, a day following phase 2b results were shared at CHEST.

Clinicians now have pharmacologic and nonpharmacologic treatments that can be very effective for the common condition.

There's a perfect storm brewing that makes telemedicine an inevitability in the management of conditions like asthma and COPD.

An expert delves into the machinations of Type 2 asthma inflammation — a common condition in moderate-to-severe asthma patients.

The Cleveland Clinic's study of CDC-collected data from 1999 to 2015 showed one age group's resilience to asthma mortality.

While advanced therapies approved for either should be considered for ACO patients, there hasn't be sole investigations.

After implementing a team-based care approach to COPD, one hospital saved $600 per patient, per year.

Nitrogen dioxide, particulate matter, elemental carbon, and winter average sulfur dioxide were more prevalent in high asthma prevalence neighborhoods.

Ambient air pollution-related deaths now total more annually than AIDS, tuberculosis, and malaria combined.

As COPD exacerbations continue to plague patients, the AIRWISE trial will examine LAMA/LABA/ICS combinations.

The CAPSTONE-1 trial demonstrated a new antiviral aimed to reduce flu symptoms with possible NDA submission.

In total, 774 cases of nightmares were reported, with 467 of the cases occurring in patients aged 19 years and younger using montelukast.

The URECA showed that early exposure to cat, mouse, and cockroach allergens can reduce the risk of asthma by age 7.

“We are constantly looking for new molecules with which to treat COPD patients.”

Tezepelumab targets onset of inflammation in evidencing promise for adults with uncontrolled asthma.

Analysis of omalizumab trials has identified asthma patients who are most likely to respond to treatment.

Results from "real word" asthma treatment with omalizumab correspond to clinical trial findings and suggest that FeNO values can help predict treatment response.

The combination is the first once-daily therapy approved in the US that combines 3 active molecules in a single inhaler.

The marker could serve in treatment trials in lieu of participants prone to exacerbation and the accompanying morbidity and risk of death.

Bronchial thermoplasty was found comparable to omalizumab in an indirect comparison of their effectiveness for uncontrolled, severe asthma.

Produced by GlaxoSmithKline, 100 mg mepolizumab used in conjunction with maximal guideline-recommended therapy, showed a consistent 18% to 20% reduction.

Inhaled corticosteroid for wheezing in early childhood is effective in selected patients but does not prevent progression to asthma.

About one million US adults and adolescents live with uncontrolled, persistent asthma — despite there already being an intensive regimen of standard therapies. Dupilumab may be a missing piece to comprehensive treatment.

The CHAMPS study demonstrated that comprehensive asthma interventions proven efficacious in controlled trial settings can be effectively implemented in diverse communities.

The approval marks the first FDA-approved treatment for pulmonary arterial hypertension.

Are asthma patients being mismanaged when treatment guidelines on specialist referrals are overlooked?